Organic compounds -- part of the class 532-570 series – Organic compounds – Cyclopentanohydrophenanthrene ring system containing
Reexamination Certificate
2011-08-09
2011-08-09
Badio, Barbara P (Department: 1628)
Organic compounds -- part of the class 532-570 series
Organic compounds
Cyclopentanohydrophenanthrene ring system containing
Reexamination Certificate
active
07994352
ABSTRACT:
Process for preparing 3α-7α(β)-dihydroxy-6α(β)-alkyl-5β-cholanic acid (I) in which R is a linear or branched C1-C5alkyl and the relative intermediates 3α-hydroxy-6β-alkyl-7-keto-5β-cholanic (VIII) and 3α-hydroxy-6α-alkyl-7-keto-5β-cholanic (IX).
REFERENCES:
patent: 4892868 (1990-01-01), Castagnola et al.
patent: 4921848 (1990-05-01), Frigerio et al.
patent: 5061701 (1991-10-01), Pellicciari et al.
patent: 5128481 (1992-07-01), Oda et al.
patent: 5175320 (1992-12-01), Pellicciari et al.
patent: 6200998 (2001-03-01), Sahoo et al.
patent: 6559188 (2003-05-01), Gatlin et al.
patent: 6639078 (2003-10-01), Haffner et al.
patent: 6777446 (2004-08-01), Houze et al.
patent: 6906057 (2005-06-01), Forman et al.
patent: 6984650 (2006-01-01), Haffner et al.
patent: 6987121 (2006-01-01), Kliewer et al.
patent: 7138390 (2006-11-01), Pellicciari
patent: 2002/0094977 (2002-07-01), Robl et al.
patent: 2002/0120137 (2002-08-01), Houze et al.
patent: 2002/0132223 (2002-09-01), Forman et al.
patent: 2003/0130296 (2003-07-01), Bauer et al.
patent: 0101554 (1984-02-01), None
patent: 0124068 (1984-11-01), None
patent: 0135782 (1985-04-01), None
patent: 0186023 (1986-07-01), None
patent: 312867 (1989-04-01), None
patent: 0393493 (1990-10-01), None
patent: 1137940 (2001-10-01), None
patent: 1140079 (2001-10-01), None
patent: 1165135 (2002-01-01), None
patent: 1185277 (2002-03-01), None
patent: 1378749 (2004-01-01), None
patent: 1473042 (2004-11-01), None
patent: 1536812 (2005-06-01), None
patent: 1568706 (2005-08-01), None
patent: 1947108 (2008-07-01), None
patent: WO-9728149 (1997-08-01), None
patent: WO-9736579 (1997-10-01), None
patent: WO-9802159 (1998-01-01), None
patent: WO-9938845 (1999-08-01), None
patent: WO-0025134 (2000-05-01), None
patent: WO-0037077 (2000-06-01), None
patent: WO-0040965 (2000-07-01), None
patent: WO-0057915 (2000-10-01), None
patent: WO-0076523 (2000-12-01), None
patent: WO-0130343 (2001-05-01), None
patent: WO-9731907 (2001-06-01), None
patent: WO-0220463 (2002-03-01), None
patent: WO-02064125 (2002-08-01), None
patent: WO 02/072598 (2002-09-01), None
patent: WO-03015771 (2003-02-01), None
patent: WO-03015777 (2003-02-01), None
patent: WO-03016280 (2003-02-01), None
patent: WO-03016288 (2003-02-01), None
patent: WO-03030612 (2003-04-01), None
patent: WO-03043581 (2003-05-01), None
patent: WO 03/080803 (2003-10-01), None
patent: WO-03086303 (2003-10-01), None
patent: WO-03090745 (2003-11-01), None
patent: WO-200400752 (2004-01-01), None
patent: WO-2004048349 (2004-06-01), None
patent: WO-2005032549 (2005-04-01), None
patent: WO-2005082925 (2005-09-01), None
patent: WO-2005089316 (2005-09-01), None
patent: WO-2006122977 (2006-11-01), None
patent: WO-2008002573 (2008-01-01), None
patent: WO-2008091540 (2008-07-01), None
patent: WO-2010/059853 (2010-05-01), None
Mangelsdorf, David J. et al; “The RXR Heterodimers and Orphan Receptors”; Cell, vol. 83; 841-850; Dec. 15, 1995.
Forman, Barry M. et al; “Identification of a Nuclear Receptor That Is Activated by Farnesol Metabolites”; Cell; vol. 81; 687-693; Jun. 2, 1995.
Pellicciari, Roberto et al.; “Bile Acid Derivatives as Ligands of the Farnesoid X Receptor. Synthesis, Evaluation and Structure-Activity Relationship of a Series of Body and Side Chain Modified Analogues of Chenodeoxycholic Acid”; Journal of Med. Chem., 47(18), 4559-4569 CODEN: JMCMAR 2004.
Pellicciari, Roberto et al; “6.Alpha.-Ethyl-Chenodeoxycholic Acid (6-ECDCA), a Potent and Selective FXR Agonist Endowed with Anticholestatic Activity”; Journal of Med. Chem., 45(17), 3569-3572 CODEN: JMCMAR 2002.
Aldini et al., “Relationship between structure and intestinal absorption of bile acids with a steroid or side-chain modification”,Steroids, 61(10):590-597 (1996).
Bishop-Bailey et al., “Expression and activation of the farnesoid X receptor in the vasculature”,Proc. Natl. Acad. Sci. U.S.A., 101(10):3668-3673 (2004).
Clerici et al., “Effect of Intraduodenal Administration of 23-Methyl-UDCA Diastereoisomers on Bile Flow in Hamsters”,Dig. Dis. Sci., 37(5):791-798 (1992).
Fiorucci et al., “The Nuclear Receptor SHP Mediates Inhibition of Hepaptic Stellate Cells by FXR and Protects Against Liver Fibrosis”,Gastroenterology, 127:1497-1512 (2004).
Fukuchi et al., “5β-Cholane activators of the farnesol X receptor”,J. Steroid Biochem. Mol. Biol., 94(4):311-318 (2005).
Haslewood et al., “Specificity and some characteristics of a 7.alpha.-hydroxysteroid dehydrogenase fromE. coli”, Database accession No. 1978:419015, 1998.
Honorio et al., “Hologram QSAR Studies on Farnesoid X Receptor Activators”,Lett. Drug Des. Dis., 3(4):261-267 (2006).
Kihira et al., “Synthesis of sulfonate analogs of bile acids”,Steroids, 57(4):193-198 (1992).
Kim et al., “Hypocholesterolemic Effect of Bile Acid Sulfonate Analogs in Hamsters”,Biol.Pharm. Bulletin, 24(3):218-220 (2001).
Kliewer et al., “Peroxisome Proliferator-Activated Receptors: From Genes to Physiology”,Endo J., 56:239-263 (2001).
Mi et al., “Structural Basis for Bile Acid Binding and Activation of the Nuclear Receptor FXR”,Mol. Cell, 11:1093-1100 (2003).
Mikami et al., “Effect of some sulfonate analogues of ursodeoxycholic acid on biliary lipid secretion in the rat”,J. Lipid Res., 37(6)1181-1188 (1996).
Miki et al., “Sulfonate analogues of chenodeoxycholic acid: metabolism of sodium 3α, 7α-dihydroxy-25-homo-5β-cholane-25-sulfonate and sodium 3α, 7α-dihydroxy-24-nor-5β-cholane-23-sulfonate in the hamster”,J. Lipid Res., 33(11):1629-1637 (1992).
Nesto et al., “Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure”,Diabetes Care, 27(1):256-263 (2004).
Pellicciari et al.,“Nongenomic Actions of Bile Acids. Synthesis and Preliminary Characterization of 23- and 6,23-Alkyl-Substituted Bile Acid Derivatives as Selective Modulators for the G-Protein Coupled Receptor TGR5”,J. Med. Chem., 50:4265-4268 (2007).
Raskin et al., “A Randomized Trial of Rosiglitazone Therapy in Patients With Inadequately Controlled Insulin-Treated Type 2 Diabetes”,Diabetes Care, 24(7):1226-1232 (2001).
Roda et al., “23-Methyl-3α.,7β-dihydroxy-5β-cholan-24-oic Acid: Dose-Response Study of Biliary Secretion in Rat”,Hepatol., 8(6):1571-1576 (1988).
Roda et al., “Bile acids with a cyclopropyl-containing side chain. IV. Physicochemical and biological properties of the four diastereoisomers of 3α,7β-dihydroxy-22,23-methylene-5β-cholan-24-oic acid”,J. Lipid Res., 28(12):1384-1397 (1987).
Rubin et al., “Combination Therapy With Pioglitazone and Insulin in Patients With Type 2 Diabetes”,Diabetes, 48(Suppl. 1):A110 (1999) (Abstract Only).
Sato et al., “Novel Potent and Selective Bile Acid Derivatives as TGR5 Agonists: Biological Screening, Structure-Activity Relationships, and Molecular Modeling Studies”,J. Med. Chem., 51(6):1831-1841 (2008).
Schmider et al., “Evidence for an additional sinusoidal bile salt transport system”, Database accession No. 2000:260886, Feb. 16, 2009.
Souillac et al., “Characterization of Delivery Systems, Differential Scanning Calorimetry”, inEncyclopedia of Controlled Drug Delivery, John Wiley & Sons, pp. 212-227 (1999).
Stenner et al., “The effect of ursodeoxycholic acid on fibrosis markers in alcoholic liver disease”,Flak Symposium, pp. 229-235 (2002).
Vippagunta et al., “Crystalline solids”,Adv. Drug Del. Rev., 48:3-26 (2001).
Willson et al., “The PPARs: From Orphan Receptors to Drug Discovery”,J. Med. Chem., 43(4):527-550 (2000).
Ferrari Massimo
Pellicciari Roberto
Badio Barbara P
Elrifi, Esq. Ivor R.
Intercept Pharmaceuticals, Inc.
Loebach Jennifer L.
Mintz Levin Cohn Ferris Glovsky and Popeo P.C.
LandOfFree
Process for preparing... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Process for preparing..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Process for preparing... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2666411